Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Trial details
- Registry ID
- NCT03672292
- Phase
- Phase 2
The FDA approved Voriconazole on 24 May 2002.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisNCT03672292 | SCYX | Phase 2 | Terminated | 2023-03-27Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2002-05-24Day | Voriconazole | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021266", "applicant_as_listed_by_fda": "PF PRISM CV", "brand_names": ["VFEND"], "active_ingredients": ["VORICONAZOLE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20020524", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |